June 19, 2013 4:11 AM ET

Pharmaceuticals

Company Overview of Ascendis Pharma A/S

Company Overview

Ascendis Pharma A/S, a pharmaceutical company, focuses on the development and marketing of specialty drugs for the therapeutic areas of endocrinology, central nervous system disorders, and infectious diseases. Its products include ACP-001, a TransCon PEG growth hormones for growth hormone deficiency; TransCon Hydrogel Insulin, a once-weekly basal insulin to reduce the risk of hypoglycemia for the diabetic patient while ensuring glycemic control for a week; TransCon Hydrogel GLP-1, a formulation of a GLP-1 agonist for the treatment of type II diabetes; and TransCon PEG Interferon α for the treatment of Hepatitis C. The company also provides TransCon Hydrogel Insulin/GLP-1, a fixed dose i...

Detailed Description

Tuborg Boulevard 12

Hellerup,  2900

Denmark

Founded in 2007

Phone:

45 36 94 44 86

Fax:

45 36 94 40 10

www.ascendispharma.com

Key Executives for Ascendis Pharma A/S

Chairman and Acting Chief Financial Officer
Chief Administrative Officer and General Manager
Acting Chief Medical Officer
Vice President of Product Development and Alliance Management
Chief Scientific Officer
Compensation as of Fiscal Year 2012.

Ascendis Pharma A/S Key Developments

United Therapeutics Corporation Announces Collaboration with Ascendis Pharma to Develop Self-Injectable Treprostinil for Pulmonary Arterial Hypertension
Sep 20 12

United Therapeutics Corporation announced that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient in Remodulin(R) (treprostinil) injection. United Therapeutics believes that the TransCon technology platform may enable a controlled, long-acting release of a novel, carrier-linked product, significantly enhancing the delivery profile of treprostinil by establishing a self-injectable alternative for patients who currently use the drug via a continuous infusion pump for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, United Therapeutics will also have exclusive rights to develop prostacyclin, prostacyclin analog and prostacyclin-related products for treatment of PAH using the TransCon technology, and will hold worldwide commercial rights to products resulting from the collaboration.

Similar Private Companies By Industry

Company Name Region
BIOresearch A/S Europe
ENKAM Pharmaceuticals A/S Europe
Zymenex A/S Europe
HotWatch ApS Europe
Mcneil Denmark Aps Europe

Recent Private Companies Transactions

Type
Date		 Target
No transactions available in the past 12 months.
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ascendis Pharma A/S, please visit www.ascendispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close